TOP > 外国特許検索 > KIT AND METHOD FOR SELECTING CANCER PATIENTS FOR WHOM ADMINISTRATION OF ANTIBODY PHARMACEUTICAL FOR HER2 PROTEINS, WHICH ARE THERAPEUTIC TARGET MOLECULES, IS EFFECTIVE

KIT AND METHOD FOR SELECTING CANCER PATIENTS FOR WHOM ADMINISTRATION OF ANTIBODY PHARMACEUTICAL FOR HER2 PROTEINS, WHICH ARE THERAPEUTIC TARGET MOLECULES, IS EFFECTIVE UPDATE

外国特許コード F170009145
整理番号 (S2016-0364-N0)
掲載日 2017年8月8日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP002645
国際公開番号 WO 2017131066
国際出願日 平成29年1月26日(2017.1.26)
国際公開日 平成29年8月3日(2017.8.3)
優先権データ
  • 特願2016-014465 (2016.1.28) JP
発明の名称 (英語) KIT AND METHOD FOR SELECTING CANCER PATIENTS FOR WHOM ADMINISTRATION OF ANTIBODY PHARMACEUTICAL FOR HER2 PROTEINS, WHICH ARE THERAPEUTIC TARGET MOLECULES, IS EFFECTIVE UPDATE
発明の概要(英語) The present invention provides a kit and a method for selecting cancer patients for whom the administration of an antibody pharmaceutical for HER2 proteins, which are therapeutic target molecules, is effective. The kit contains a lateral flow immunoassay test strip that has a structure in which there are connected, in sequence from the upstream side in the direction of sample flow, a sample pad where a sample is added, a conjugate pad that holds first anti-HER2 protein antibodies, a membrane that has a region where second anti-HER2 protein antibodies and antibodies that bind to the first anti-HER2 protein antibodies are immobilized, and an absorbent pad, wherein an antibody pharmaceutical for HER2 proteins, which are therapeutic target molecules, is used for either of the first anti-HER2 protein antibodies and the second anti-HER2 protein antibodies. The method according to the present invention includes a step for detecting HER2 proteins in the cancer tissue of a patient by lateral flow immunoassay using this test strip.
特許請求の範囲(英語) [claim1]
1. Being the kit in order to select the cancer patient whose dosage of the antibody medicine which designates the HER2 protein as the remedy target molecule is effective, it included the test strip for lateral flow immunoassay in order to detect the HER2 protein which is in the midst of cancer organizing, as for the said test strip, the sample pad which adds the sample from to high-level order of the machine direction the sample, the conjugation pad where the first anti- HER2 protein antibody is kept, the second anti- HER2 protein antibody to solid phase the territory where it is converted and the antibody which is connected to the first anti- HER2 protein antibody was connected to solid phase the membrane, and the absorption pad which possess the territory where it is convertedThe kit which features that it possesses constitution, the aforementioned first anti- HER2 protein antibody and either of the second anti- HER2 protein antibodies on the one hand, it uses the aforementioned antibody medicine.
[claim2]
2. The aforementioned antibody medicine, torasutsuzumabu, perutsuzumabu and torasutsuzumabu - the m tongue thin from the group which consists of in the claim 1 which features that it is selected the kit of statement.
[claim3]
3. The aforementioned first anti- HER2 protein antibody with the colloid particulate the sign in the claim 1 which features that it is done or 2 the kit of statement.
[claim4]
4. In either of the claim 1-3 which features that the aforementioned antibody medicine is used for the aforementioned first anti- HER2 protein antibody the kit of statement.
[claim5]
5. In either of the claim 1-3 which features that the aforementioned antibody medicine is used for the aforementioned second anti- HER2 protein antibody the kit of statement.
[claim6]
6. In either of the claim 1-3 which features that it is the aforementioned antibody medicine to which the aforementioned membrane, the third anti- HER2 protein antibody to solid phase the territory where it is converted, or, the third anti- HER2 protein antibody to solid phase the territory where it is converted and the fourth anti- HER2 protein antibody to solid phase furthermore includes the territory where it is converted, as for the aforementioned second anti- HER2 protein antibody, the aforementioned third anti- HER2 protein antibody and the aforementioned fourth anti- HER2 protein antibody differs respectively the kit of statement.
[claim7]
7. In either of the claim 1-6 which features that the protein extract which is manufactured from the cancer organization which was picked from the subject is designated as the sample the kit of statement.
[claim8]
8. In the claim 7 which features that the aforementioned cancer organization is biopsy organization the kit of statement.
[claim9]
9. In the claim 7 which features that the aforementioned cancer organization is cancer organization of the upper alimentary canal or 8 the kit of statement.
[claim10]
10. Being the method of selecting the cancer patient whose dosage of the antibody medicine which designates the HER2 protein as the remedy target molecule is effective, the method of featuring that it includes the process (1)-(3) below:
(1) the process which manufactures the sample from the cancer organization which was picked from the subject,
The process which detects the HER2 protein in the aforementioned sample (2) with the lateral flow immunoassay which uses the antibody medicine which designates the aforementioned HER2 protein as the remedy target molecule, and
(3) the process which selects the subject who shows positivity with the aforementioned lateral flow immunoassay.
[claim11]
11. The aforementioned antibody medicine, torasutsuzumabu, perutsuzumabu and torasutsuzumabu - the m tongue thin from the group which consists of in the claim 10 which features that it is selected method of statement.
[claim12]
12. In the aforementioned process (2), from in high-level order of the machine direction the sample, the aforementioned first anti- HER2 protein antibody and either of the second anti- HER2 protein antibodies on the one hand the sample pad which adds the sample, the conjugation pad where the first anti- HER2 protein antibody is kept, the second anti- HER2 protein antibody to solid phase the territory where it is converted and the antibody which is connected to the first anti- HER2 protein antibody to solid phase making use of the test strip for lateral flow immunoassay which possesses the constitution where the membrane, and the absorption pad which possess the territory where it is converted are connected, the claim which features that the aforementioned antibody medicine is usedIn section 10 or 11 method of statement.
[claim13]
13. The aforementioned first anti- HER2 protein antibody with the colloid particulate the sign in the claim 12 which features that it is done method of statement.
[claim14]
14. In the claim 12 which features that the aforementioned antibody medicine is used for the aforementioned first anti- HER2 protein antibody or 13 method of statement.
[claim15]
15. In the claim 12 which features that the aforementioned antibody medicine is used for the aforementioned second anti- HER2 protein antibody or 13 method of statement.
[claim16]
16. In the claim 12 which features that it is the antibody medicine to which the aforementioned membrane, the third anti- HER2 protein antibody to solid phase the territory where it is converted, or, the third anti- HER2 protein antibody to solid phase the territory where it is converted and the fourth anti- HER2 protein antibody to solid phase furthermore includes the territory where it is converted, as for the aforementioned second anti- HER2 protein antibody, the aforementioned third anti- HER2 protein antibody and the aforementioned fourth anti- HER2 protein antibody differs respectively or 13 method of statement.
[claim17]
17. In either of the claim 10-16 which features that the aforementioned cancer organization is biopsy organization method of statement.
[claim18]
18. In either of the claim 10-17 which features that the aforementioned cancer organization is cancer organization of the upper alimentary canal method of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KYOTO UNIVERSITY
  • 発明者(英語)
  • MUTO MANABU
  • YOSHIOKA MASAHIRO
国際特許分類(IPC)
指定国 (WO2017131066)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください。

PAGE TOP

close
close
close
close
close
close